Premier Diagnostic Center,
With cancer, you MUST advocate for yourself. Here's an example why... Recently, a woman with ER positive breast cancer called…
Cancer Treatment Options And Management Inc,
With cancer, you MUST advocate for yourself. Here's an example why... Recently, a woman with ER positive breast cancer called…
Instituto Oncológico de Andalucía,
http://www.nejm.org/doi/full/10.1056/NEJMoa1701830?utm_source=facebook
Thai Breast Disease Society,
Recurrence Risk Lasts Decades After Breast Cancer Treatment: Rises with tumor traits over 20 years
Premier Diagnostic Center,
Recently, a woman with ER positive breast cancer called us for advice. She had recently been diagnosed with T1 stage cancer and…
Cancer Treatment Options And Management Inc,
Recently, a woman with ER positive breast cancer called us for advice. She had recently been diagnosed with T1 stage cancer and…
Equipo de Soporte y Cuidados Paliativos,
After 5 yrs of endocrine therapy in women with ER+, early-stage #breastcancer, recurrences continue to occur steadily for up to…
Association of Oncology Social Work (AOSW),
Disappointing
ASIP Breast Cancer Scientific Interest Group,
http://www.nejm.org/doi/full/10.1056/NEJMoa1701830?query=featured_home
Stoffwechselzentrum Rhein-Pfalz,
After 5 yrs of endocrine therapy in women with ER+, early-stage #breastcancer, recurrences continue to occur steadily for up to…
Labome News,
The most recent The New England Journal of Medicine study reports #breast_cancer recurrence risk lingers years after treatment…
Colegio Médicos Postgraduados IMSS A.C.,
After 5 yrs of endocrine therapy in women with ER+, early-stage #breastcancer, recurrences continue to occur steadily for up to…
The New England Journal of Medicine,
After 5 yrs of endocrine therapy in women with ER+, early-stage #breastcancer, recurrences continue to occur steadily for up to…
Ecografia Dott. Massa,
https://www.ncbi.nlm.nih.gov/pubmed/29117498
Cancer News Ceprec,
Original Article from The New England Journal of Medicine — 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine…
ONS Cancer Genetics SIG,
Original Article from The New England Journal of Medicine — 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine…
Breast Cancer Action Germany,
Wichtige Veröffentlichung zu zwei Fragen: Hormontherapie und Langzeitüberleben - leider nur eine Kurzfassung online frei zugängli…
eToims Physical Rejuvenation System,
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5…
Ask Nurse Santos,
Are you a breast cancer survivor? Maybe it's time to talk with your oncologist about this new information about the recurrence…
Internet Medical Association,
Related…
Talbot Research Library & Media Services,
20-Year Risks of #BreastCancer Recurrence after Stopping Endocrine Therapy at 5 Years NEJM https://t.co/gj8nTWWFkt
Nancy's Point,
The risk for recurrence remains. We've known this to be true for a while, but this study adds additional proof that ER+ breast…
Tom Heston MD,
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. N Engl J Med. 2017 Nov 09;377(19):1836-1…
岸和田市乳腺外科専門医のページ,
乳がん術後に5年間のホルモン療法を受けた症例の再発は診断から20年まで確実に持続。再発リスクは原発がんのT因子・N因子・グレードと相関しており、20年累積遠隔再発率はT1N0で15%、T2N2で41%、T1N0 / Low grade で10%、T1N0 …